Agilent ClinGuide CRISPR sgRNA for Human Therapeutics

Accelerate the clinical success of therapeutic gene editing programs



ClinGuide CRISPR sgRNA delivers the high-quality current Good Manufacturing Practices (cGMP) material that you need to meet the rigorous requirements of human clinical trials.

Agilent is here to support you during the advancement of your lead single guide RNA (sgRNA) oligonucleotide therapeutic candidates through clinical trials to commercialization.

We understand the importance of high-quality cGMP manufacturing, timely delivery of material, and the need for robust support throughout your program.

2 cGMP manufacturing sites, inspected by U.S. FDA

$725M investment into two new manufacturing lines by 2026

Our highly skilled team is uniquely qualified to develop analytical methods and RNA synthesis manufacturing processes that optimize purity and yield for your specific guide RNA. Agilent has consistently demonstrated manufacturing success across a large range of scales.

For more than two decades, we have delivered solutions for oligo development, manufacturing, in-process testing, raw materials analysis, drug substance release, and stability testing. We now apply this experience and commercialization expertise to sgRNA manufacturing to produce high-quality material.

ClinGuide capabilities:

- Lightly to heavily modified sequences
- Highly scalable manufacturing
- High-resolution purity testing
- cGMP expertise from clinical to commercial

Learn more at:
www.agilent.com/chem/clinguide

Agilent
Trusted Answers

Produce cGMP material at scale

Confidently produce chemically modified guide RNA for human therapeutic use with Agilent. We adhere to strict cGMP practices for robust, scalable, efficient, and safe sgRNA manufacturing—such as documentation, traceability, and quality standards.

Move seamlessly to manufacturing

As a contract development and manufacturing organization (CDMO), we have two cGMP facilities in Colorado that are equipped for multiple products and projects. We continue to expand our sgRNA manufacturing capacities and capabilities.

cGMP synthesis team and suite

cGMP ultrafiltration suite

Ensure high purity of your CRISPR molecule

Our rigorous, phase-appropriate quality systems incorporate cGMP standards and the Quality by Design approach. Agilent uses highly resolving impurity methods that are compatible with mass spectrometry to ensure your guide is of high quality.

Partner with our team

Partner with a team that's deeply invested in your long-term success. From day one, your project manager will coordinate a cross-functional team to gain a clear understanding of your requirements and ensure successful project completion.

Agilent LC/MS instruments are used to identify and control impurities

The business development and project management team is invested in your success

Together, we can enable better decision making, solve problems, and see your project through to completion. Accelerate the clinical success of your therapeutic gene editing program with Agilent.

Learn more at **www.agilent.com/chem/clinguide**

PR7001-1538
This information is subject to change without notice.

Published in the USA, September 25, 2023
5994-6705EN

Agilent
Trusted Answers